Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,086 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,118
- Phase 1823
- Phase 1/Phase 2484
- Phase 3349
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma333
- Acute Myeloid Leukemia292
- Lymphoma182
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Mantle Cell Lymphoma62
- Anemia60
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center60
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama146
- Arizona123
- Florida111
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,086 total
- NCT07494565RecruitingPhase 2
Celecoxib plus standard chemo for CD5+ DLBCL
This trial tests whether adding celecoxib (an anti-inflammatory drug) to the standard R-CHOP chemotherapy regimen can improve outcomes for people with a specific, hard-to-treat type of diffuse large B-cell lymphoma (DLBCL) that is CD5-positive. It's for people who are newly diagnosed and have advanced disease.
Guangzhou, GuangdongAges 18–80 - NCT07719556RecruitingPhase 2
Orelabrutinib with obinutuzumab and venetoclax for untreated MCL
This trial tests a new combination of three targeted drugs (orelabrutinib, obinutuzumab, and venetoclax) for people with newly diagnosed mantle cell lymphoma who have not had treatment before. The goal is to see if this short-course combination can effectively control the disease while being gentle on the body.
Changzhou, JiangsuAges 18 years+ - NCT07236502Recruiting
Moving forward with myeloma: Exercise and lifestyle program
This study tests a lifestyle program with exercise and nutrition guidance for people who have had multiple myeloma for at least one year. The goal is to see if it helps improve daily wellbeing and strength.
Maywood, IllinoisAges 18 years+ - NCT07441694RecruitingPhase 1
Study of INCA036978 for blood cancers
This trial tests a new drug called INCA036978 for people with a group of blood cancers called myeloproliferative neoplasms (MPNs), including myelofibrosis, polycythemia vera, and essential thrombocythemia. It aims to see if the drug is safe and works well.
Birmingham, AlabamaAges 18 years+ - NCT05973656Recruiting
Study how alcohol affects the risk of mouth cancer
This study looks at how a breakdown product from alcohol (acetaldehyde) may play a role in oral (mouth) cancer. It may help researchers understand who is more affected by alcohol and why.
Minneapolis, MinnesotaAges 18–45 - NCT07422480RecruitingPhase 3
Comparing elritercept to epoetin alfa for anemia in MDS needing transfusions
This trial tests a new drug called elritercept against a standard treatment, epoetin alfa, for people with a low-risk form of MDS who need regular blood transfusions for anemia. The goal is to see if elritercept works better to reduce the need for transfusions.
Gilbert, ArizonaAges 18 years+ - NCT07069699RecruitingPhase 1/Phase 2
Testing a new drug for lymphoma with MYC gene changes
This trial tests the safety of a new drug, CX-5461 (Pidnarulex), in people with certain types of aggressive B-cell lymphoma that have specific MYC gene changes. It aims to find out if this drug can help when standard treatments are no longer working.
Irvine, CaliforniaAges 18 years+ - NCT06160791RecruitingPhase 2
Ruxolitinib with reduced chemo for HLH treatment
This trial tests a combination of a targeted drug (ruxolitinib) with a less intense version of standard chemo for adults with Hemophagocytic Lymphohistiocytosis (HLH). It aims to control the overactive immune response while reducing side effects.
Irvine, CaliforniaAges 18 years+ - NCT07285005RecruitingPhase 3
Study of an oral drug for venous, lymphatic, and certain overgrowth syndromes
This trial tests whether the study drug KP-001 can help reduce symptoms like pain, fatigue, or bleeding caused by certain vascular malformations (abnormal blood vessel growths) that can't be surgically removed or haven't responded to other treatments. It's for people age 2 and older with specific conditions such as common venous malformations, lymphatic malformations, or KTS/CLOVES syndrome.
Charleston, South CarolinaAges 2 years+ - NCT07347249RecruitingPhase 2
New drug for congenital Factor VII deficiency
This study tests a new drug called Sutacimig for people with congenital Factor VII deficiency, a rare bleeding disorder. The drug is designed to help prevent or control bleeding episodes.
LondonAges 18–60 - NCT04227847RecruitingPhase 1
Study of a CD70-targeting drug for blood cancer
This Phase 1 study tests the safety of SEA-CD70, a drug that targets CD70, in people with certain blood cancers like MDS and AML. It may help doctors learn whether this approach can be used safely for patients whose disease has come back or not responded to standard treatments.
Birmingham, AlabamaAges 18 years+ - NCT05861050RecruitingPhase 1/Phase 2
Study of 4-drug treatment for newly diagnosed high-risk mantle cell lymphoma
This trial tests a combination of medicines to treat newly diagnosed high-risk mantle cell lymphoma (MCL). It may help shrink the lymphoma and improve outcomes, especially for people whose disease has higher-risk features.
Duarte, CaliforniaAges 18–80 - NCT07094048RecruitingPhase 4
Immunoglobulins for multiple myeloma patients on BCMA T-cell engagers
This trial tests whether giving immunoglobulins (a treatment to boost your immune system) helps multiple myeloma patients who are receiving a BCMA-directed T-cell engager therapy. It aims to see if this can reduce infections and improve outcomes.
Lévis, QuebecAges 18 years+ - NCT07549698RecruitingPhase 1/Phase 2
CRISPR Gene Therapy for Immune Blood Disorders
This trial tests CTX112, a new CRISPR gene therapy that modifies your immune cells to treat severe immune thrombocytopenic purpura (ITP) or warm autoimmune hemolytic anemia (WAIHA) that hasn't responded to standard treatments. The goal is to see if it's safe and can help your body stop attacking its own blood cells.
Rochester, MinnesotaAges 18 years+ - NCT07457151Recruiting
Danicopan study for PNH in Korea
This trial is studying danicopan as an add-on therapy for people with paroxysmal nocturnal hemoglobinuria (PNH) who are already taking a C5 inhibitor like eculizumab or ravulizumab. It aims to see how well danicopan works when used together with these standard treatments.
BusanAges Any age - NCT07008118RecruitingPhase 1
Study of INCA035784 for certain blood cancers
This trial tests a new drug, INCA035784, for people with myeloproliferative neoplasms (MPNs), a group of blood cancers. It may help if your MPN is called myelofibrosis (MF) or essential thrombocythemia (ET) and has a specific genetic change (CALR mutation), and you've already tried other treatments.
Phoenix, ArizonaAges 18 years+ - NCT07709195RecruitingPhase 2
Chlorophyllin to reduce mouth sores from radiation before transplant
This trial tests whether taking chlorophyllin can reduce mouth sores caused by total body radiation given before a stem cell transplant. The goal is to make the treatment easier to tolerate.
Navi Mumbai, MaharashtraAges 12–65 - NCT07476183RecruitingPhase 1
Testing APR-2020 for RPS19-deficient Diamond-Blackfan Anemia
This trial is testing a new treatment called APR-2020 for children and young adults with a specific type of Diamond-Blackfan Anemia (caused by a change in the RPS19 gene). The goal is to see if this treatment is safe, tolerable, and can help reduce the need for blood transfusions.
Stanford, CaliforniaAges 2–25 - NCT07718204Recruiting
Medication help for kids after bone marrow transplant
This study tests a program that helps caregivers remember to give their child's oral medications after a bone marrow transplant. If you are the main caregiver for a child who had a transplant and is still in the hospital, this trial might be for you.
Columbus, OhioAges birth–12 years - NCT07548710RecruitingPhase 2
SA plus X for newly diagnosed AML
This trial tests a combination of two drugs, SA and X, for people who have just been diagnosed with acute myeloid leukemia (AML) and have not yet received treatment (except hydroxyurea to lower white blood cells). The goal is to see if the combination works better than standard care.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT04504526RecruitingEarly Phase 1
New imaging for diagnosing lymphoma
This study tests a new imaging method called CXCR4 PET/CT that may help doctors better see and understand lymphomas (a type of blood cancer). It is for people who are newly diagnosed or suspected of having lymphoma and have already had a standard PET/CT.
Fuzhou, FujianAges 18–80 - NCT07101705RecruitingEarly Phase 1
Testing OriV508 for blood cancers that haven't responded to treatment
This study tests a new treatment called OriV508 for people with blood cancers (multiple myeloma or aggressive B-cell lymphoma) that have not responded to at least two previous therapies. It aims to see if the treatment is safe and helps shrink or control the cancer.
Wuhan, HubeiAges 18–75 - NCT05473910RecruitingPhase 1
Engineered donor T cells after stem cell transplant for blood cancers
This trial tests specially engineered donor T cells (TSC-100 or TSC-101) given after a stem cell transplant to help prevent cancer relapse in people with AML, MDS, or ALL. It is for patients who have a specific genetic marker (HA-1 or HA-2) and a matched donor.
Duarte, CaliforniaAges 18 years+ - NCT06892522RecruitingPhase 1/Phase 2
T cell therapies for multiple myeloma
This trial tests new antibody treatments for multiple myeloma, given alone or with other drugs. It aims to see if they can control the disease and what side effects might occur.
Duarte, CaliforniaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,086 recruiting hematology studies from the U.S. registry right now, out of 7,699 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.